Group One Trading’s BioMarin Pharmaceuticals BMRN Stock Holding History

Group One Trading’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$621K	Sell	11,000 -5,400	-33%	-$315K	﹤0.01%	3149
2025 Q4	$975K	Buy	16,400 +2,800	+21%	+$152K	﹤0.01%	2913
2025 Q3	$737K	Sell	13,600 -97,900	-88%	-$5.6M	﹤0.01%	3309
2025 Q2	$6.13M	Sell	111,500 -71,900	-39%	-$4.23M	0.01%	1163
2025 Q1	$13M	Sell	183,400 -26,500	-13%	-$1.78M	0.04%	504
2024 Q4	$13.8M	Buy	209,900 +6,500	+3%	+$435K	0.03%	528
2024 Q3	$14.3M	Sell	203,400 -10,100	-5%	-$844K	0.04%	425
2024 Q2	$17.6M	Buy	213,500 +69,200	+48%	+$5.76M	0.07%	245
2024 Q1	$12.6M	Sell	144,300 -2,000	-1%	-$179K	0.05%	342
2023 Q4	$14.1M	Buy	146,300 +100,600	+220%	+$8.9M	0.04%	499
2023 Q3	$4.04M	Sell	45,700 -38,800	-46%	-$3.45M	0.01%	1079
2023 Q2	$7.32M	Buy	84,500 +49,500	+141%	+$4.66M	0.02%	704
2023 Q1	$3.4M	Sell	35,000 -95,000	-73%	-$9.85M	0.01%	1098
2022 Q4	$13.5M	Sell	130,000 -64,500	-33%	-$6.06M	0.03%	574
2022 Q3	$16.5M	Buy	194,500 +67,800	+54%	+$6.04M	0.03%	481
2022 Q2	$10.5M	Buy	126,700 +6,800	+6%	+$541K	0.02%	805
2022 Q1	$9.24M	Sell	119,900 -96,600	-45%	-$8.08M	0.01%	1060
2021 Q4	$19.1M	Sell	216,500 -23,400	-10%	-$1.93M	0.02%	705
2021 Q3	$18.5M	Sell	239,900 -1,200	-0.5%	-$94.7K	0.02%	656
2021 Q2	$20.1M	Sell	241,100 -53,400	-18%	-$4.23M	0.02%	629
2021 Q1	$22.2M	Buy	294,500 +65,200	+28%	+$5.33M	0.03%	495
2020 Q4	$20.1M	Buy	229,300 +50,600	+28%	+$4.01M	0.03%	443
2020 Q3	$13.6M	Buy	178,700 +52,700	+42%	+$5.33M	0.04%	400
2020 Q2	$15.5M	Buy	126,000 +55,900	+80%	+$5.56M	0.07%	300
2020 Q1	$5.92M	Sell	70,100 -6,400	-8%	-$551K	0.05%	455
2019 Q4	$6.47M	Sell	76,500 -64,100	-46%	-$4.84M	0.04%	536
2019 Q3	$9.48M	Sell	140,600 -54,300	-28%	-$4.18M	0.08%	294
2019 Q2	$16.7M	Buy	194,900 +141,600	+266%	+$12.1M	0.15%	122
2019 Q1	$4.74M	Sell	53,300 -39,700	-43%	-$3.68M	0.05%	453
2018 Q4	$7.92M	Buy	93,000 +24,900	+37%	+$2.37M	0.07%	325
2018 Q3	$6.6M	Sell	68,100 -5,200	-7%	-$519K	0.05%	447
2018 Q2	$6.91M	Buy	73,300 +29,200	+66%	+$2.56M	0.06%	389
2018 Q1	$3.58M	Sell	44,100 -330,900	-88%	-$28.4M	0.04%	647
2017 Q4	$33.4M	Buy	375,000 +279,300	+292%	+$24.3M	0.24%	64
2017 Q3	$8.91M	Sell	95,700 -51,200	-35%	-$4.52M	0.08%	293
2017 Q2	$13.3M	Buy	146,900 +51,300	+54%	+$4.67M	0.14%	155
2017 Q1	$8.39M	Sell	95,600 -51,200	-35%	-$4.55M	0.1%	234
2016 Q4	$12.2M	Sell	146,800 -40,200	-21%	-$3.46M	0.12%	174
2016 Q3	$17.3M	Buy	187,000 +98,100	+110%	+$9.24M	0.19%	100
2016 Q2	$6.92M	Sell	88,900 -3,500	-4%	-$298K	0.08%	268
2016 Q1	$7.62M	Sell	92,400 -17,900	-16%	-$1.46M	0.11%	211
2015 Q4	$11.6M	Sell	110,300 -82,000	-43%	-$8.56M	0.14%	136
2015 Q3	$20.3M	Sell	192,300 -51,400	-21%	-$6.87M	0.28%	49
2015 Q2	$33.3M	Buy	243,700 +44,400	+22%	+$5.5M	0.47%	19
2015 Q1	$24.8M	Buy	199,300 +96,300	+93%	+$10.2M	0.39%	29
2014 Q4	$9.31M	Buy	103,000 +37,000	+56%	+$3.08M	0.14%	131
2014 Q3	$4.76M	Sell	66,000 -27,300	-29%	-$1.79M	0.07%	311
2014 Q2	$5.8M	Buy	93,300 +58,100	+165%	+$3.51M	0.09%	242
2014 Q1	$2.4M	Sell	35,200 -33,200	-49%	-$2.45M	0.04%	536
2013 Q4	$4.81M	Buy	68,400 +59,800	+695%	+$4.06M	0.07%	269
2013 Q3	$621K	Buy	+8,600	New	+$572K	0.01%	1426

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading's BMRN Position: Q1 2026 in Review

Group One Trading sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 7,641 shares — an estimated $446K sold.

Group One Trading first reported a position in BMRN in Q3 2013 and held it in 43 quarters. The position peaked at $12.5M in Q4 2020. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Group One Trading reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Group One Trading sold 7,641 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $446K.
Group One Trading first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 43 quarters.
Group One Trading's BioMarin Pharmaceuticals position peaked at $12.5M in Q4 2020.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.